Aperture Biotech

Quantitative research on small-cap biotech stocks

By Quantitative Biotech Investing

· Launched a year ago

2026 Biotech M&A By the Numbers

A full breakdown of 46 acquisitions this year, and what the data says about how the market is pricing biotech risk
18 hrs ago·Aperture Biotech

Trading the Odds on AXSM's Rare 95% Probability FDA Decision

A profitable commercial biotech with a label expansion catalyst Thursday
Apr 28·Aperture Biotech

This Week in Biotech - 2 FDA Decisions & 3 Earnings

The week ahead in catalysts, readouts, and what is worth watching
Apr 27·Aperture Biotech

Trading the Odds Behind Tomorrow's NTLA Phase 3 Data Readout

Phase 1/2 data, short interest, options positioning, and the math on what positive data means
Apr 26·Aperture Biotech

A Profitable Biotech Just Hit Rock Bottom With Three FDA Dates This Year

you can't get much more stacked than this
Apr 24·Aperture Biotech

The Cancer Biotech Trading at $49M With $47M in Cash

When the cash nearly equals the market cap, you are getting the drug for almost nothing.
Apr 23·Aperture Biotech

CNTX: Three Cancer Drugs And Only $148M Enterprise Value

A 15-person company with $66 million in cash and a June data readout that could change everything.
Apr 20·Aperture Biotech

Subscribers Asked, I'm Answering: 4 Tickers Under the Microscope

A new deep dive series built entirely from your requests.
Apr 16·Aperture Biotech

Aperture Biotech

Quantitative research on small-cap biotech stocks